These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38416402)

  • 1. SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.
    Wolff AW; Peine J; Höfler J; Zurek G; Hemker C; Lingor P
    CNS Drugs; 2024 Apr; 38(4):291-302. PubMed ID: 38416402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).
    Wolff AW; Bidner H; Remane Y; Zimmer J; Aarsland D; Rascol O; Wyse RK; Hapfelmeier A; Lingor P
    Front Aging Neurosci; 2024; 16():1308577. PubMed ID: 38419648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
    Takata M; Tanaka H; Kimura M; Nagahara Y; Tanaka K; Kawasaki K; Seto M; Tsuruma K; Shimazawa M; Hara H
    Br J Pharmacol; 2013 Sep; 170(2):341-51. PubMed ID: 23763343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract.
    Hinderling PH; Karara AH; Tao B; Pawula M; Wilding I; Lu M
    J Clin Pharmacol; 2007 Jan; 47(1):19-25. PubMed ID: 17192498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.
    Lingor P; Weber M; Camu W; Friede T; Hilgers R; Leha A; Neuwirth C; Günther R; Benatar M; Kuzma-Kozakiewicz M; Bidner H; Blankenstein C; Frontini R; Ludolph A; Koch JC;
    Front Neurol; 2019; 10():293. PubMed ID: 30972018
    [No Abstract]   [Full Text] [Related]  

  • 7. Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia.
    Takase S; Liao J; Liu Y; Tanaka R; Miyagawa Y; Sawahata M; Sobue A; Mizoguchi H; Nagai T; Kaibuchi K; Ozaki N; Yamada K
    Eur J Pharmacol; 2022 Sep; 931():175207. PubMed ID: 35987254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.
    Shimokawa H; Hiramori K; Iinuma H; Hosoda S; Kishida H; Osada H; Katagiri T; Yamauchi K; Yui Y; Minamino T; Nakashima M; Kato K
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):751-61. PubMed ID: 12409984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.
    Shibuya M; Hirai S; Seto M; Satoh S; Ohtomo E;
    J Neurol Sci; 2005 Nov; 238(1-2):31-9. PubMed ID: 16005902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons.
    Yamashita K; Kotani Y; Nakajima Y; Shimazawa M; Yoshimura S; Nakashima S; Iwama T; Hara H
    Brain Res; 2007 Jun; 1154():215-24. PubMed ID: 17482584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage.
    Satoh S; Takayasu M; Kawasaki K; Ikegaki I; Hitomi A; Yano K; Shibuya M; Asano T
    J Pharmacol Sci; 2012; 118(1):92-8. PubMed ID: 22186620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
    Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
    Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.
    Suzuki Y; Shibuya M; Satoh S; Sugiyama H; Seto M; Takakura K
    Neurol Med Chir (Tokyo); 2008 Jun; 48(6):241-7; discussion 247-8. PubMed ID: 18574328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.
    Hata T; Goto C; Soga J; Hidaka T; Fujii Y; Idei N; Fujimura N; Maruhashi T; Mikami S; Kihara Y; Chayama K; Noma K; Liao JK; Higashi Y
    Atherosclerosis; 2011 Jan; 214(1):117-21. PubMed ID: 21035804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
    Hibma JE; O'Gorman M; Nepal S; Pawlak S; Ginman K; Pithavala YK
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):71-81. PubMed ID: 34698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
    Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
    J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.